Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06015776 · ClinicalTrials.gov registry record
Purinergic Signaling and the Postmenopausal Heart
A clinical trial of Heart Failure With Preserved Ejection Fraction and Diastolic Heart Failure, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT06015776: Recruiting study of Heart Failure With Preserved Ejection Fraction and Diastolic Heart Failure, sponsored by Beth Israel Deaconess Medical Center.
NCT06015776 is a study of Heart Failure With Preserved Ejection Fraction and Diastolic Heart Failure that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 500 participants, below the 2,276-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06015776, a study of Heart Failure With Preserved Ejection Fraction and Diastolic Heart Failure, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
Primary Outcome
Expression of CD39, ADORA2A and ADORA2B in cardiac tissue measured using Western blotting
Conditions Studied
Interventions
- OTHER Gender
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-07-01 |
| Est. Completion | 2030-06 |
What NCT06015776 shows while recruiting
NCT06015776 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, below the 2,276-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which Gender is the first listed.
NCT06015776 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06015776 about?
NCT06015776 is a clinical study titled "Purinergic Signaling and the Postmenopausal Heart". There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic r...
What is the current status of trial NCT06015776?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-07-01. Estimated completion is 2030-06.
What conditions does trial NCT06015776 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction, Diastolic Heart Failure.
What interventions are being tested in trial NCT06015776?
The interventions under investigation include: Gender (OTHER).
Who is sponsoring clinical trial NCT06015776?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06015776 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06015776's enrollment target sits among peer trials
500 8th of 42 higher than 35 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
RECRUITING · NA
-
Matching Perfusion and Metabolic Activity in HFpEF
RECRUITING · Phase 2
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
RECRUITING · Phase 3
-
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI